## All Wales Medicines Strategy Group

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan



## WEDNESDAY 23<sup>rd</sup> MARCH 2016 COMMENCING 09:30 AM AT <u>CARDIFF METROPOLITAN UNIVERSITY</u>, LLANDAFF CAMPUS, WESTERN AVENUE, CARDIFF CF5 2YB

## **AGENDA**

**Enclosure** 

- 1. Welcome and introduction
- 2. Apologies
- 3. Declarations of interest
- 4. Minutes of previous meeting

1/AWMSG/0316

To protect commercial confidentiality the following appraisal will be held in private

5. Appraisal 1: Full Submission (WPAS)
Sorafenib (Nexavar®) for the treatment of hepatocellular carcinoma

**2**/AWMSG/0316 Appendices

The meeting will now open to the public (approximately 10.30am)

- 6. Chairman's report (verbal update)
- 7. Appraisal 2: Full Submission
  Ulipristal acetate (Esmya®) for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age

3/AWMSG/0316 Appendices

8. Appraisal 3: Limited Submission
Prucalopride (Resolor®) for the symptomatic treatment of chronic constipation in men in whom laxatives fail to provide adequate relief

**4**/AWMSG/0316 Appendices

Date of next meeting: 20th April 2016 in Cardiff